Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis.
Five patients with a severe form of chronic progressive multiple sclerosis no longer responsive to steroid therapy were treated for six months with high-dose intravenous immunoglobulin associated with plasmalymphocytapheresis and azathioprine. In spite of an apparent initial stabilization of the course of the disease, EDSS assessment after six and twelve months of therapy revealed progressive disability in all patients.
Uccelli
A
A
Istituto di Clinica Neurologica e C.N.R. Centro per la Neurofisiologia Cerebrale, Università di Genova.
Capello
E
E
Fenoglio
D
D
Incagliato
M
M
Valbonesi
M
M
Mancardi
G L
GL
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008212:Lymphocyte Depletion; D009103:Multiple Sclerosis / Q000503:physiopathology / Q000628:therapy*; D010956:Plasmapheresis; D013997:Time Factors; D017211:Treatment Failure
D016756:Immunoglobulins, Intravenous; D001379:Azathioprine